In fact, other than clinical failures in HNSCC, MEK1/2 inhibitors, such as CI-1040, was also demonstrated to be ineffective against solid tumors with trials halted at Phase II settings29,30. Here, MAP2K1 is linked to head and neck squamous cell carcinoma.